---
title: "Purchase of Nanobodies and epitope mapping for grant funded project"
ocid: "ocds-h6vhtk-05f155"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-05f155"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-05f155.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-05f155.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "MHRA"
published: "2025-12-09"
---

# Purchase of Nanobodies and epitope mapping for grant funded project

Buyer: MHRA  
Current stage: Award  
OCID: ocds-h6vhtk-05f155

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-05f155)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-05f155.json)

## Summary

The Medicines and Healthcare products Regulatory Agency (MHRA), a central government public authority based in London, United Kingdom, has completed the procurement process for a project titled "Purchase of Nanobodies and epitope mapping for grant funded project." This contract, worth €80,000 with a gross amount of €96,000, covers laboratory services, laboratory reagents, and medical analysis services crucial to the healthcare and biopharmaceutical industry. The procurement method adopted was direct, without competition, due to the time-sensitive nature and specific expertise required for the project. The contract was awarded to Proteogenix SAS, a large supplier based in Schiltigheim, France. The document was officially signed on 10th November 2025, and the contract period is from 11th November 2025 to 10th November 2026.

This tender presents significant opportunities for businesses specialising in producing laboratory reagents and advanced medical analysis services. Firms with capabilities in protein expression, especially those focusing on nanobody sequences, stand to gain substantially by positioning themselves as key suppliers in similar direct award contexts. The specificity and time constraints outlined in this contract highlight an environment in which nimble, experienced businesses in niche biopharmaceutical markets can excel and expand their market reach, particularly in serving public authorities engaged in high-priority, grant-financed projects.

## Notice

The very important time constrains (before 20th of March 2026) attached to the awarded grant finance, for our specific objective, This supplier expertise with expressing our nanobody sequences in different formats, their speed, competitive pricing and MHRA's prior in house validation of nanobody products made by this supplier , makes this supplier in our view the only provider that can realistically meet our request within the allocated timelines. Protein production can be outsourced from several commercial entities, but the trade for companies that have relevant and ample experience in nanobody expression, at small scale, in a cost-effective and time-saving manner to fulfil our request is limited. Further, the timeline to complete the objectives of the project with the awarded grant finance translates into the inability to search, outsource, trial and validate the suitability of nanobodies produced by other suppliers unknown to MHRA, significantly narrowing feasible possibilities.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/080869-2025 |
| Notice type | UK7 - Contract Details Notice |
| Procurement type | Standard |
| Procurement category | Goods |
| Procurement method | Direct |
| Procurement method details | Below threshold - without competition |
| Tender suitability | Not specified |
| Awardee scale | Large |
| All stages | Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 9 Dec 2025 |
| Submission deadline | Not specified |
| Future notice date | Not specified |
| Award date | 10 Nov 2025 |
| Contract period | 11 Nov 2025 - 10 Nov 2026 |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | Not specified |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £80,000 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Complete |
| Awards status | Active |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | MHRA |
| Locality | LONDON |
| Post town | East London |
| Postcode | E14 4PU |
| Country | England |
| ITL 1 | TLI London |
| ITL 2 | TLI4 Inner London - East |
| ITL 3 | TLI42 Tower Hamlets |
| Local authority | Tower Hamlets |
| Electoral ward | Canary Wharf |
| Westminster constituency | Poplar and Limehouse |
| Delivery location | Not specified |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 1 |
| Supplier names | PROTEOGENIX |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products
- 71 - Architectural, construction, engineering and inspection services
- 85 - Health and social work services

### Codes

- 33696500 - Laboratory reagents
- 71900000 - Laboratory services
- 85148000 - Medical analysis services

## Release History

- 9 Dec 2025 at 08:34 - Award - UK7 - Contract Details Notice - https://www.find-tender.service.gov.uk/Notice/080869-2025

## Documents

- https://www.find-tender.service.gov.uk/Notice/080869-2025
  9th December 2025 - Contract details notice on Find a Tender

## Notice URLs

- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
- https://www.legislation.gov.uk/ukpga/2023/54/contents

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-05f155. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-05f155.json.